No CrossRef data available.
Article contents
Behavioral impairments in a mouse model of Kabuki syndrome associated with dopaminergic and neuroinflammatory modulations
Published online by Cambridge University Press: 14 April 2025
Abstract
Kabuki syndrome is a rare multisystem congenital disorder characterized by specific facial malformations and several other symptoms, including motor impairments, increased susceptibility to infections, immune mediators’ deficits, anxiety, and stereotyped behaviors. Considering the reports of motor impairments in Kabuki syndrome patients, the first hypothesis of the present study was that this motor dysfunction was a consequence of striatal dopaminergic modulation. The second hypothesis was that the peripheral immune system dysfunctions were a consequence of neuroinflammatory processes. To study these hypotheses the mutant bapa mouse was used as it is a validated experimental model of Kabuki syndrome.
Exploratory behavior, anxiety-like behavior (light-dark test), repetitive/stereotyped behavior (spontaneous and induced self-grooming), and tyrosine hydroxylase (TH), astrocyte glial fibrillary acidic protein (GFAP), and ionized calcium-binding adaptor molecule 1 (Iba1) striatal expressions were evaluated in female adult bapa and control mice.
Female bapa mice did not present anxiety-like behavior, but exploratory hyperactivity and stereotyped behavior both on the spontaneous and induced self-grooming tests. Striatal TH, GFAP, and Iba1 expressions were also increased in bapa mice.
The exploratory hyperactivity and the stereotyped behavior occurred in detriment of the striatal dopaminergic system hyperactivity and a permanent neuroinflammatory process.
- Type
- Original Article
- Information
- Creative Commons
- This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
- Copyright
- © The Author(s), 2025. Published by Cambridge University Press on behalf of Scandinavian College of Neuropsychopharmacology